ME00591B - Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencije - Google Patents
Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencijeInfo
- Publication number
- ME00591B ME00591B MEP-2009-31A MEP3109A ME00591B ME 00591 B ME00591 B ME 00591B ME P3109 A MEP3109 A ME P3109A ME 00591 B ME00591 B ME 00591B
- Authority
- ME
- Montenegro
- Prior art keywords
- ischemic
- antibody
- retinopathy
- dii4
- antibody fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Terapijs k i postupak za lečenje i shemijskih ili vaskularnih poremećaja primenjivanjem sredstva koje može inhibisati aktivnost humanog delta-sličnog liganda 4 (0114) subjektu kome je to neophodn o . Poželjn o , sredstvo je an t i - 0114 antitelo ili fragment antitela koji mogu inhibisati vezivanje 0114 za Notch recepto r . U jednom ostvarenj u , ishemijski ili vaskularni poremećaj j e : ishemijska povred a , cerebralna ishemij a , srčana ishemij a , ishemijska stanja koja se javljaju u udovima i drugim organima ili tkivim a , arteriovenske malformacij e , zarastanje ran a , transplantacija organa ili tkiv a , insuficijencija placent e , arterijalno sužavanje i okluzij a , ateroskleroza i sistemska ili plućna hipertenzij a . U drugom ostvarenj u , lečena bolest je bolest oka ili stanje kao što j e : retinopatija kod preranog rođenj a , ishemijska retinopatij a , okluzija vene ili arterije mrežnjač e , retinopatija posledica dijabet a , horoidna neovaskula r i zacij a , makularna degeneracija povezana sa starenje m , neovaskulariza c i j a rož n j ač e , neovaskularni glaukom i transplantacija rožnjače .
Claims (7)
1.Upotreba sredstva koje može da inhibira DII4 aktivnost za proizvodnju leka za lečenje, inhibiranje ili poboljšavanje ishemijskog ili vaskularnog poremećaja, u kojoj DII4 antagonist sadrži antitelo ili fragment antitela koji mogu blokirati vezivanje DII4 za Notch receptor ili sadrži fragment DII4, opciono povezan za multimerizujuću komponentu.
2.Upotreba, kao u patentnom zahtevu 1, u kojoj je DII4 antitelo ili fragment antitela poliklonsko ili monoklonsko.
3.Upotreba, kao u patentnom zahtevu 2, u kojoj je antitelo ili fragment antitela humanizovan, himerični ili potpuno humano antitelo ili fragment antitela.
4.Upotreba, kao u ma kom od patentnih zahteva 1 do 3, gde je ishemijski ili vaskularni poremećaj bolest oka ili stanje koje se opisuje prisustvom abnormalnih krvnih sudova i/ili gubitkom normalnih krvnih sudova ili sudovne funkcije.
5.Upotreba, kao u patentnom zahtevu 4, gde je bolest oka: retinopatija preranog rođenja, ishemijska retinopatija, venska ili arterijska okluzija u mrežnjači, retinopatija kao posledica dijabeta, horoidna neovaskularizacija, makularna degeneracija povezana sa starenjem, neovaskularizacija rožnjače, neovaskularni glaukom ili transplantacija rožnjače.
6.Upotreba, kao u ma kom od patentnih zahteva 1 do 5, pri kojoj je subjekt koji se leči ljudsko biće.
7.Upotreba, kao u ma kom od patentnih zahteva 1 do 3, gde je ishemijski ili vaskularni poremećaj: ishemijska povreda, cerebralna ishemija, ishemija srca, ishemijska stanja koja pogađaju udove i druge organe ili tkiva, arteriovenske malformacije, zarastanje rana, transplantacija organa ili tkiva, insuficijencija placente, arterialno sužavanje ili okluzija, ateroskleroza i sistemska ili plućna hipertenzija.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83600306P | 2006-08-07 | 2006-08-07 | |
| PCT/US2007/017546 WO2008019144A2 (en) | 2006-08-07 | 2007-08-07 | Threapeutic methods for treating vascular eye disorders with dll4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ME00591B true ME00591B (me) | 2011-12-20 |
| ME00591A ME00591A (en) | 2011-12-20 |
Family
ID=38904599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-31/09A ME00591A (en) | 2006-08-07 | 2007-08-07 | Use of dii4 antagonists in ishemic injury or vascular insufficiency |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080181893A1 (me) |
| EP (1) | EP2054082B1 (me) |
| JP (1) | JP5529536B2 (me) |
| KR (1) | KR101497355B1 (me) |
| CN (1) | CN101500605B (me) |
| AU (1) | AU2007281916B2 (me) |
| BR (1) | BRPI0716424B8 (me) |
| CA (1) | CA2660235C (me) |
| CO (1) | CO6150190A2 (me) |
| CR (1) | CR10627A (me) |
| DK (1) | DK2054082T3 (me) |
| ES (1) | ES2398253T3 (me) |
| GT (1) | GT200900029A (me) |
| HR (1) | HRP20130271T1 (me) |
| IL (1) | IL196612A (me) |
| MA (1) | MA30667B1 (me) |
| ME (1) | ME00591A (me) |
| MX (1) | MX2009000674A (me) |
| MY (1) | MY150092A (me) |
| NO (1) | NO341857B1 (me) |
| NZ (1) | NZ574794A (me) |
| PL (1) | PL2054082T3 (me) |
| PT (1) | PT2054082E (me) |
| RS (1) | RS52685B (me) |
| RU (1) | RU2429876C2 (me) |
| SG (1) | SG174033A1 (me) |
| SI (1) | SI2054082T1 (me) |
| SV (1) | SV2009003161A (me) |
| TN (1) | TN2009000036A1 (me) |
| UA (1) | UA95304C2 (me) |
| WO (1) | WO2008019144A2 (me) |
| ZA (1) | ZA200900337B (me) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| WO2008091222A1 (en) * | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| JP5859307B2 (ja) * | 2008-09-10 | 2016-02-10 | ジェネンテック， インコーポレイテッド | 眼の血管新生を阻害する方法 |
| RU2581962C2 (ru) | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Нацеленные средства связывания, направленные на dll4, и их применение |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| WO2011008641A1 (en) | 2009-07-13 | 2011-01-20 | Beth Israel Deaconess Medical Center, Inc. | Methids of modulating angiogenesis and treatment of angiogenesis-related diseases |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| ES2700450T3 (es) * | 2009-10-16 | 2019-02-15 | Oncomed Pharm Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| BR112012021941A2 (pt) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| EP2906295A4 (en) * | 2012-10-15 | 2016-06-01 | Oncomed Pharm Inc | METHOD FOR THE TREATMENT OF EYE DISEASES |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| US9931199B2 (en) * | 2014-05-05 | 2018-04-03 | Roberto Gustavo ALBERTAZZI | Methods and apparatus for treating keratoconus |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| WO2018094267A1 (en) * | 2016-11-17 | 2018-05-24 | Children's Medical Center Corporation | Novel methods to enhance microvascular engraftment of bioengineered and primary tissues |
| WO2023063842A1 (ru) | 2021-10-12 | 2023-04-20 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующая слитый белок |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| EP1928486A2 (en) * | 2005-09-01 | 2008-06-11 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| KR20090016762A (ko) * | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
-
2007
- 2007-08-07 ME MEP-31/09A patent/ME00591A/xx unknown
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/ko active Active
- 2007-08-07 HR HRP20130271TT patent/HRP20130271T1/hr unknown
- 2007-08-07 EP EP07811137A patent/EP2054082B1/en active Active
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/ru active
- 2007-08-07 RS RS20130078A patent/RS52685B/sr unknown
- 2007-08-07 ES ES07811137T patent/ES2398253T3/es active Active
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/da active
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/es active IP Right Grant
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/zh active Active
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
- 2007-08-07 SI SI200731170T patent/SI2054082T1/sl unknown
- 2007-08-07 PT PT78111374T patent/PT2054082E/pt unknown
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 CA CA2660235A patent/CA2660235C/en active Active
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/en not_active Ceased
- 2007-08-07 PL PL07811137T patent/PL2054082T3/pl unknown
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/pt active IP Right Grant
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/ja active Active
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 UA UAA200902033A patent/UA95304C2/ru unknown
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
-
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/fr unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/es unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/es unknown
- 2009-02-20 CR CR10627A patent/CR10627A/es unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/fr unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/no unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00591B (me) | Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencije | |
| Bae et al. | Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial | |
| Park et al. | Iatrogenic retinal artery occlusion caused by cosmetic facial filler injections | |
| Sacu et al. | Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion | |
| JP2015528454A5 (me) | ||
| Higashide et al. | Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma | |
| Blankenship et al. | Retinal tributary vein occlusion: history and management by photocoagulation | |
| Moon et al. | Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis | |
| Yamamoto et al. | Central retinal artery occlusion after radial optic neurotomy in a patient with central retinal vein occlusion | |
| An et al. | Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion | |
| Dumitrache | Ophtalmological pathology and management of ocular disease in retinal metabolic phacomatosis | |
| RU2575966C2 (ru) | Способ лечения неоваскулярной глаукомы | |
| Li et al. | Clinical research of EX-PRESS drainage device and modified trabeculectomy combined with intravitreal conbercept treatment for neovascular glaucoma | |
| Kayikcioglu et al. | Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide | |
| Froehler et al. | Angiographic investigation of orbital vascular variations in the rabbit and implications for endovascular intra-arterial chemotherapy models | |
| Wasik et al. | Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma | |
| Yamamoto et al. | Neovascular glaucoma after branch retinal artery occlusion | |
| Kitnarong et al. | Aflibercept as adjunctive treatment for filtration surgery in neovascular glaucoma | |
| Marticorena et al. | Retinal angiomatous proliferation | |
| CY1113840T1 (el) | Χρηση ανταγωνιστων d114 σε ισχαιμικη βλαβη ή αγγειακη ανεπαρκεια | |
| Bennet | Pegaptanib for the treatment of ischemic retinopathy in patients with diabetes and retinal vascular occlusive disorders | |
| Al-Droos et al. | The effect of intravitreal avastin on systemic blood pressure in controlled hypertensive patients | |
| Ignatiev | The Choice of Method of Treatment for Macular Edema in Patients Following Retinal Vein Occlusion | |
| Sukmono et al. | Branch Retinal Vein Occlusion with Vitreous Hemorrhage Identified During Intraoperative Vitrectomy | |
| Niu et al. | Acute visual loss in an orbital arteriovenous malformation |